Perspective Therapeutics (CATX) 10-Q 2024 Q2 Quarterly report

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Perspective Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Johan (Thijs) Spoor, Chief Executive Officer of the Company, Jonathan Hunt, Chief Financial Officer, and Mark J. Austin, Vice President of Finance and Corporate Controller, of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2024

/s/ Johan (Thijs) Spoor

Johan (Thijs) Spoor

Chief Executive Officer
(Principal Executive Officer)

/s/ Jonathan Hunt

Jonathan Hunt

Chief Financial Officer
(Co-Principal Financial Officer)

/s/ Mark J. Austin

Mark J. Austin

Vice President of Finance and Corporate Controller
(Co-Principal Financial Officer, Principal Accounting Officer, Corporate Secretary)